A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Several minimal derivatives of RK2 have been prepared. In these plasmids most of the genes have been removed, leaving only genes essential for replication and one or more selectable markers. One such "mini-replicon" is the plasmid PFF1, which is 5873 basepairs long. PFF1 consists of an origin of replication, oriV, an origin of transfer, oriT, a gene coding for plasmid replication proteins, trfA, and two antibiotic resistance genes, bla and cat, which confer resistance to ampicillin and chloramphenicol, respectively. Minimal plasmids such as PFF1 are useful for studying the basic mechanisms of plasmid replication and copy number regulation, as there are less superfluous genetic elements which might affect the processes being studied. Several mutants of PFF1 which affect the copy number of the plasmid have been identified. Two such mutants, PFF1cop254D and PFF1cop271C, increase the copy number of PFF1 in E. coli from approximately 39-40 to about 501 and 113 plasmids per cell, respectively. An increase in copy number is useful for genetic engineering applications to increase the production yield of recombinant protein.
In ABO and Rh typing, reagents containing antibodies against the A, B, and RhD antigens are added to suspensions of blood cells. If the relevant antigen is present, the red blood cells will demonstrate visible agglutination (clumping). In addition to identifying the ABO antigens, which is termed forward grouping, routine ABO blood typing also includes identification of the ABO antibodies in the person's plasma. This is called reverse grouping, and it is done to confirm the ABO blood type. In reverse grouping, the person's plasma is added to type A1 and type B red blood cells. The plasma should agglutinate the cells that express antigens that the person lacks, while failing to agglutinate cells that express the same antigens as the patient. For example, the plasma of someone with type A blood should react with type B red cells, but not with A1 cells. If the expected results do not occur, further testing is required. Agglutination is scored from 1+ to 4+ based on the strength of the reaction. In ABO typing, a score of 3+ or 4+ indicates a positive reaction, while a score of 1+ or 2+ is inconclusive and requires further investigation.
Many readers have puzzled over the ending of Ubik, when Glen Runciter finds a Joe Chip coin in his pocket. What does it mean? Is Runciter dead? Are Joe Chip and the others alive? Actually, this is meant to tell you that we can't be sure of anything in the world that we call 'reality.' It is possible that they are all dead and in cold pac or that the half-life world can affect the full-life world. It is also possible that they are all alive and dreaming. Peter Fitting sees parallels between the God-Devil/Life-Death relationship of Ubik and the antagonist's consumptive abilities within half-life, and the commercialized industry between psychics and psychic-inhibiting "inertials" which occupies the novel's "reality". Fitting also notes Dick's effort to desacralize and commercialize Ubik through the ironic advertising messages which begin each chapter.
28 December – A new model of the largest neutron stars finds an 80–90% chance that they contain quark-matter cores. 29 December – A metascience study estimates the total amount of article processing charges paid to publish with open access in journals controlled by the five large commercial publishers from 2015–2018 to be $1.06 billion. On 12 December, it is reported that the number of paper retractions has hit a new record of over 10,000 in 2023, with around 80% coming from journals owned by Hindawi, mostly special issues overseen by guest editors. Promising innovations relating to global challenges are reported: a flying firehose robot, the Dragon Firefighter (22 Dec), completion of the first functional 105 meters tall more-modular Modvion wooden wind turbine is reported (28 Dec). Promising results of health and medical research are reported: news reports about a portable EEG helmet with significant accuracy of decoding thought words to text, DeWave (12 Dec), carrots against cancer-risk (17 Dec).
This list of sequenced animal genomes contains animal species for which complete genome sequences have been assembled, annotated and published. Substantially complete draft genomes are included, but not partial genome sequences or organelle-only sequences. For all kingdoms, see the list of sequenced genomes.
Sources: en.wikipedia.org
== Gold nanoparticles in skin care and cosmetics == The utilization of gold in skin care and cosmetics dates back at least to the 1st century B.C in Egypt, where Queen Cleopatra is said to have used masks made from gold to maintain her skin complexion. It was said that she used it every night to enhance her complexion and improve the suppleness of her skin. Nowadays, gold has made its way into various skincare products such as lotion and cream, as well as skincare treatments such as facial masks. Gold in skincare products are usually in the form of colloidal gold, or more commonly called nanogold. These nanoparticles ranges in size from 5 nm to 400 nm. This section will discuss about the effect of gold nanoparticle in wound healing application together with the effect of gold in lotion and cream products.
Daisy was the most famous campaign commercial of the Cold War. Aired only once, on 7 September 1964, it was a factor in Lyndon B. Johnson's defeat of Barry Goldwater in the 1964 presidential election. The contents of the commercial were controversial, and their emotional impact was searing. The commercial opens with a very young girl standing in a meadow with chirping birds, slowly counting the petals of a daisy as she picks them one by one. Her sweet innocence, along with mistakes in her counting, endear her to the viewer. When she reaches "9", an ominous-sounding male voice is suddenly heard intoning the countdown of a rocket launch. As the girl's eyes turn toward something she sees in the sky, the camera zooms in until one of her pupils fills the screen, blacking it out. The countdown reaches zero, and the blackness is instantly replaced by a simultaneous bright flash and thunderous sound which is then followed by footage of a nuclear explosion, an explosion similar in appearance to the near surface burst Trinity test of 1945, followed by another cut to footage of a billowing mushroom cloud. As the fireball ascends, an edit cut is made, this time to a close-up section of incandescence in the mushroom cloud, over which a voiceover from Johnson is played, which states emphatically, "These are the stakes! To make a world in which all of God's children can live, or to go into the dark. We must either love each other, or we must die." Another voiceover then says, "Vote for President Johnson on November 3.
Branco ("White") is a rare variety local to the Amazon estuary in which the berries do not change color, but remain green when ripe. This is believed to be due to a recessive gene since only about 30% of 'Branco' palm seeds mature to express this trait. BRS-Pará was developed in 2004 by the Brazilian Agricultural Research Agency. The pulp yield ranges from 15% to 25%. BRS Pai d'Égua is the newest cultivar developed by the Brazilian Agricultural Research Agency.
When NAD+ levels are low, nicotinic acid mononucleotide (NaMN) can bind to the allosteric region and inhibit SARM1 activity, thus explaining the potent axon protection provided by treating neurons with the NaMN precursor nicotinic acid riboside (NaR) while inhibiting NAMPT. Chemical screening approaches have also identified covalent inhibitors of SARM1's allosteric ARM domain region. Other pro-degeneration signaling pathways, such as the MAP kinase pathway, have been linked to SARM1 activation. MAPK signaling has been shown to promote the loss of NMNAT2, thereby promoting SARM1 activation. SARM1 activation also triggers the MAP kinase cascade, indicating some form of feedback loop may exist.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.